Neurocrine Biosciences, Inc.’s (NBIX) share price has entered into oversold territory with an RSI value of 26.0. The Zacks Consensus Estimate on Neurocrine Biosciences, Inc.’s earnings for the full year period has loss of 0.08 cents over the past two months to $0.70 per share. Currently, Neurocrine Biosciences, Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (NBIX) after its recent drop.
NEUROCRINE BIOSCIENCES INC (NBIX): Free Stock Analysis Report
Zacks Investment Research
- Investment & Company Information
- Neurocrine Biosciences